Ron Aoyama
Gilead Sciences (United States)(US)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Melanoma and MAPK Pathways, Mathematical Biology Tumor Growth, PI3K/AKT/mTOR signaling in cancer, HIV Research and Treatment
Most-Cited Works
- → A Refined 3-Dimensional QSAR of Cytochrome P450 2C9: Computational Predictions of Drug Interactions(2000)91 cited
- → Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor(2012)79 cited
- → Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)(2013)65 cited
- → Preclinical Disposition of GDC-0973 and Prospective and Retrospective Analysis of Human Dose and Efficacy Predictions(2012)35 cited
- → SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors(2012)34 cited
- → Discovery and Characterization of an Inhibitor of Glucosylceramide Synthase(2012)20 cited
- → Discovery of potent and selective inhibitors of calmodulin-dependent kinase II (CaMKII)(2017)11 cited
- → Preclinical characterization of a non-peptidomimetic HIV protease inhibitor with improved metabolic stability(2024)4 cited
- → Supplementary Figure 1 from Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor(2023)
- → Supplementary Figure 3 from Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor(2023)